ObsEva SA (OBSV)

0.170
-0.008(-4.44%)
After Hours
0.171
+0.001(+0.647%)
- Real-time Data
  • Volume:
    549,493
  • Day's Range:
    0.165 - 0.180
  • 52 wk Range:
    0.130 - 2.920

OBSV Overview

Prev. Close
0.178
Day's Range
0.165-0.18
Revenue
24.96M
Open
0.18
52 wk Range
0.13-2.92
EPS
-0.792
Volume
549,493
Market Cap
17.15M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,692,330
P/E Ratio
-0.225
Beta
0.284
1-Year Change
-93.78%
Shares Outstanding
100,945,313
Next Earnings Date
Nov 10, 2022
What is your sentiment on ObsEva?
or
Market is currently closed. Voting is open during market hours.

ObsEva SA News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

ObsEva SA Analysis

ObsEva SA Company Profile

ObsEva SA Company Profile

Employees
48

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsNeutralSellNeutralStrong BuyStrong Sell
SummaryNeutralNeutralBuyBuyStrong Sell
  • earnings beat, beautiful
    0
    • Garbage
      0
      • garbage
        1
        • ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
          0
          • I'm hoping for a $ 28 buyout in the next 8-10 months
            0
            • Total trash
              2
              • Stay away from this SCAM
                2
                • bought at $4,15bought at $3,80bought at $3,20I bought today at $2,85. when there is an positive update or developments in pipeline this can go straight up #HoldTheLine
                  0
                  • always down. SCAM
                    2
                    • this is a joke ....
                      1
                      • patience
                        0
                      • i'm not happy either
                        0